U-50488 is a drug which acts as a highly selective
κ-opioidagonist, but without any
μ-opioidantagonist effects.[1] It has
analgesic,
diuretic and
antitussive effects,[2] and reverses the memory impairment produced by
anticholinergic drugs.[3] U-50488 was one of the first selective kappa agonists invented and research on its derivatives has led to the development of a large family of related compounds.[4][5] This compound has never received FDA approval and there are no reported human cases in the literature involving an U-50488 overdose.[6]
^Von Voigtlander PF, Lewis RA (1982). "U-50,488, a selective kappa opioid agonist: comparison to other reputed kappa agonists". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 6 (4–6): 467–70.
doi:
10.1016/S0278-5846(82)80130-9.
PMID6298890.
S2CID37011292.
^Kamei J (1996). "Role of opioidergic and serotonergic mechanisms in cough and antitussives". Pulmonary Pharmacology. 9 (5–6): 349–56.
doi:
10.1006/pulp.1996.0046.
PMID9232674.
^Hiramatsu M, Kameyama T (September 1998). "Roles of kappa-opioid receptor agonists in learning and memory impairment in animal models". Methods and Findings in Experimental and Clinical Pharmacology. 20 (7): 595–9.
doi:
10.1358/mf.1998.20.7.485724.
PMID9819804.
^Szmuszkovicz J (1999). "U-50,488 and the kappa receptor: a personalized account covering the period 1973 to 1990". Progress in Drug Research. Fortschritte der Arzneimittelforschung. Progrès des Recherches Pharmaceutiques. 52: 167–95.
doi:
10.1007/978-3-0348-8730-4_4.
PMID10396128.
^Szmuszkovicz J (1999). "U-50,488 and the kappa receptor. Part II: 1991-1998". Progress in Drug Research. Fortschritte der Arzneimittelforschung. Progrès des Recherches Pharmaceutiques. 53: 1–51.
PMID10616295.